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Abstract
Background—Large healthcare databases are increasingly used to examine the dissemination
and benefits and harms of chemotherapy treatment in routine practice, particularly among patients
excluded from trials (e.g., the elderly). Misclassification of chemotherapy could bias estimates of
frequency and association, warranting an updated assessment.
Methods—We evaluated the validity of Medicare claims to identify receipt of chemotherapy and
specific agents delivered to elderly stage II/III colorectal (CRC), in situ/early stage breast, non-
small cell lung, and ovarian cancer patients using the National Cancer Institute’s Patterns of Care
studies (POC) as the gold standard. The POC collected data on chemotherapy treatment by re-
abstracting hospital records, contacting physicians, and reviewing medical records. Patients’ POC
data were linked and compared to their Medicare claims for 2–12 months post-diagnosis. Kappa,
sensitivity (Se), specificity (Sp), positive and negative predictive values and 95% confidence
intervals were calculated for the receipt of any chemotherapy and specific agents.
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Results—Se and Sp of Medicare claims to identify any chemotherapy were high across all
cancer sites. We found substantial variation in validity across agents, by site and administration
modality. Capecitabine, an oral CRC treatment, was identified in claims with high specificity
(98%) but low sensitivity (47%), whereas oxaliplatin, an intravenously administered CRC agent
had higher sensitivity (75%) and similar specificity (97%).
Conclusions—Receipt of chemotherapy and specific intravenous agents can be identified using
Medicare claims, showing improvement from prior reports; yet, variation exists. Future studies
should assess newly-approved agents and the impact of coverage decisions for these agents under
the Medicare Part D program.
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Introduction
Chemotherapy represents an integral part of the treatment plan for many individuals
diagnosed with cancer, as it decreases the risk of recurrence and mortality in many settings.
Randomized controlled trials have documented the efficacy of chemotherapeutic agents used
to treat a variety of cancers. To examine the translation of this evidence into the routine
clinical setting, large healthcare databases, such as the Surveillance, Epidemiology, and End
Results (SEER) program-Medicare linked database, are increasingly used to conduct non-
experimental studies evaluating the uses, benefits, and harms of these treatments among
individuals excluded from trials, including older adults, those with multiple co-morbidities,
and those treated off-label.(1–26)
The validity of these studies relies upon a variety of issues, including the ability of claims
data to accurately capture treatment(s) of interest, study endpoint(s), and other important
design and clinical issues.(27) Measurement error in the assessment of chemotherapy could
lead to biased study results. Prior research supports the validity of claims data to identify
intravenously administered chemotherapy treatment for a variety of cancer sites,(28–32) but
does not address more recently approved or orally administered agents, or changes in
validity using multiple claims windows following diagnosis.
We conducted a validation study to assess the utility of Medicare claims for capturing the
receipt of any chemotherapy and specific agents delivered to patients diagnosed at age ≥65
with stage II or III colorectal cancer (CRC), in situ or early stage breast, non-small cell lung
cancer (NSCLC), or ovarian cancer. This assessment 1) evaluated the validity of selected
single agent chemotherapies, including an orally-administered agent and 2) described the
variation in measures of validity for any chemotherapy and specific treatments over multiple
follow-up periods and across cancer sites.
Methods
Data sources
We used the National Cancer Institute (NCI)’s data from the Patterns of Care studies (POC)
as the gold standard for identifying chemotherapy and the linked SEER-Medicare data as the
test source for identifying chemotherapy. The SEER program of cancer registries collects
demographic information, clinical and tumor characteristics, vital status, and cause of death
for all incident cancers reported for individuals who reside in one of the registries’ defined
geographic areas.(33)
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NCI supplements the standard SEER registry abstraction to obtain detailed information
about treatment for a subset of SEER cases. This effort, known as the POC, was developed
by NCI to investigate the dissemination of state-of-the-art cancer treatment into community
practices. These studies selected a stratified random sample of individuals (proportionate
registry size) from the SEER program 10, 12, and 13 cancer registries which covered up to
14% of the United States population.(34) All individuals were aged ≥20 years with a
histologically confirmed cancer for selected sites, stages, and years. A listing of all cancers
and stages examined by the POC are detailed elsewhere.(35) Patients were excluded if the
cancer diagnosis was determined at autopsy or on the death certificate; the diagnosis was a
second malignancy other than to a non-melanoma skin cancer; or if the individual was
simultaneously diagnosed with another cancer. Individuals were sampled by gender with
oversampling of African-Americans and Hispanics in all years and Asian/Pacific Islanders
and American Indians/Alaskan Natives in 2005 only.
In addition to the standard SEER abstraction, the POC studies supplemented information on
initial course of treatment by asking physicians (via mailed questionnaire) to verify the
treatments delivered to patients; reviewing a unified medical record (inpatient and
outpatient); and in some cases SEER registrars visited doctors’ offices to abstract data.
Requested information included whether radiation, chemotherapy or immunotherapy was
received as part of the initial course of treatment, identifying the specific agents delivered
and the dates of first administration (2005 studies only).
The SEER-Medicare data arise from a linkage of persons in the SEER data with their
Medicare enrollment, Part A (Hospital insurance) and B (Medical insurance) claims data.
These data include approximately 3.3 million elderly individuals (age ≥ 65 years) diagnosed
with cancer in one of the SEER areas or regions.(36) Approximately 94% of all elderly
individuals included in SEER have been matched to the Medicare enrollment file with an
established matching algorithm. Virtually 100% of all beneficiaries are eligible for Part A
and 93% will opt to enroll in Part B.(37)
For Medicare-eligible individuals with fee-for-service coverage, Medicare claims are
organized into files including claims for inpatient hospitalizations, durable medical
equipment (DME), outpatient hospital services, and physician and other provider services
(32). These claims encompass a multitude of information on specific service dates,
diagnoses, procedures, and agents delivered during medical encounters using various
medical coding systems. Diagnoses and procedures on hospital claims are reported using
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM)
codes. ICD-9 CM diagnosis and procedure codes can be used to identify chemotherapy
administration, but not specific agents. DME claims contain National Drug Codes (NDCs)
that can be used to identify specific oral chemotherapeutic agents that are equivalent to other
Medicare-covered intravenously administered chemotherapy agents.(38) Physician and
outpatient claims include ICD-9 CM diagnosis codes and Healthcare Common Procedure
Coding System (HCPCS) codes. HCPCS can be used to identify chemotherapy and specific
agents. Outpatient claims include revenue center codes which serve as another means of
identifying chemotherapy administration. The codes used in our analysis are presented in the
Appendix.
Study sample and eligibility criteria
The cancer sites, stages, and years of diagnoses were selected based on availability of the
POC data and included in-situ or early stage breast cancer diagnosed in 2000 and 2005,
stage II or III CRC in 2000 and 2005, NSCLC in 2005, and ovarian cancer in 2002. All POC
patients were required to be age ≥65 at cancer diagnosis; and have POC treatment
information verified through physician confirmation or a unified medical record review.
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Patients identified as being enrolled in a clinical trial were excluded because Medicare only
covers routine costs associated with federally funded clinical trials (e.g, office visits and
medical tests), and may not cover the cost of the agents themselves.(39)
This study included eligible patients in the POC data who were matched to the SEER-
Medicare data. Using the Medicare files, we required that all individuals were continuously
enrolled in Medicare Parts A and B for the 2-, 4-, 6-, 8-, 10-, or 12-month periods following
diagnosis (the post-diagnosis periods); were never enrolled in a health maintenance
organization (HMO) during the associated post-diagnosis periods; did not have a subsequent
cancer diagnosis (as reported by SEER) in the year following the qualifying POC cancer
diagnosis; and had at least one Medicare claim during the specified post-diagnosis period.
These criteria ensured that detailed claims for all individuals in the study were reported to
Medicare and were not attributable to the treatment of a subsequent cancer. Due to the time-
varying nature of these criteria, the number of individuals eligible for analysis in each post-
diagnosis period decreased over time. Details of the 6-month post-diagnosis cohort
exclusions are listed in the Appendix.
Identification of receipt of chemotherapy and specific agents in POC and SEER-Medicare
For this analysis, the POC cohort was considered the gold standard measure for the receipt
of any chemotherapy and for specific agents. Individuals were defined in POC as receiving
any chemotherapy if a physician verified or a unified medical record identified that the
individual was administered any chemotherapeutic agent. The receipt of specific agents was
identified in POC through the same mechanism. For the POC studies conducted in 2005, the
date of first administration was collected for each specific agent delivered. Therefore, the
analysis defined the initial course of treatment as the diagnosis date (set to the first day of
the month, as only month of diagnosis is reported by SEER) to 365 days following the
diagnosis date. If treatment was received outside of the year following diagnosis, it was not
considered part of the initial course of chemotherapy.
Identifying the receipt of any chemotherapy and specific agents in Medicare claims required
an examination of multiple claims files and their associated diagnosis, procedure, and drug
codes and service dates. If a claim for a general chemotherapy procedure code, a diagnosis
code for chemotherapy administration, or HCPCS code or NDC for a specific agent was
found, the individual was defined as having received chemotherapy during the specified
post-diagnosis period. The receipt of specific chemotherapy agents were defined similarly
by identifying at least one claim with a HCPCS code or NDC for the specific agent during
the post-diagnosis period.
Comparison of chemotherapy reported in POC and SEER-Medicare
Reporting of the agreement between the two data sources and the validity of chemotherapy
captured in Medicare claims was examined at interval periods using the 2, 4, 6, 8, 10 and 12-
month post-diagnosis cohorts. Specifically, we estimated the Kappa and corresponding 95%
CIs to assess concordance between the two data sources, as well as the sensitivity (Se),
specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) and
their corresponding 95% CIs of the Medicare claims definitions using the POC as the gold
standard.
We selected the specific chemotherapeutic agents to be validated based on their frequency of
use in the 6-month post-diagnosis period. Using sample size calculations, we maximized the
accuracy of the Se and Sp estimates to have a minimal acceptable lower confidence limit
that is less than 10% from the point estimate (40). Based upon this sample size calculation,
we included only specific chemotherapeutic agents where the POC reported that there were
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37 or more individuals receiving the treatment. Due to the small number of in situ and early
stage breast cancer patients receiving chemotherapy, the 2000 and 2005 POC data were
combined for analysis.
While the POC studies were considered the gold standard, they may be subject to
measurement error in their reporting of initial chemotherapy treatment. Therefore, beyond
reporting the Kappa to assess concordance between the two sources, we also conducted a
sensitivity analysis to examine the impact of potential misclassification of the gold standard
(i.e., the POC),(41) focusing on an example of oxaliplatin receipt among stage II or III CRC
patients diagnosed in 2005.
All analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC). This study was reviewed
by the University of North Carolina at Chapel Hill Institutional Review Board (IRB) and
was determined to be exempt from IRB approval.
Results
The final validation cohort included 1,187 individuals diagnosed with a primary cancer of
the breast in 2000 (n=156) or 2005 (n=155), colon or rectum in 2000 (n=171) or 2005
(n=338), lung (non-small cell only) in 2005 (n=195), and ovary in 2002 (n=170) (Table 1).
The percentage of patients receiving any chemotherapy in this cohort was 17% for in-situ/
early stage breast cancer diagnosed in 2000 and 20% in 2005; 61% for stage II/III CRC
diagnosed in 2000 and 52% in 2005; 78% for ovarian cancer diagnosed in 2002; and 49%
for NSCLC diagnosed in 2005.
Figure 1 displays the sources of chemotherapy claims found in the Medicare files (hospital,
physician, outpatient, DME, or multiple files) for all individuals included in the validation
studies by cancer site and year of diagnosis. The large majority of individuals receiving
chemotherapy only had claims reported in the physician file with very few individuals
having claims identified in the hospital file only (< 3%). However, variation by cancer site
and year of diagnosis was evident, reflecting different settings in which treatment was
delivered by site and over time. For example, the approval of capecitabine in 2005 for CRC
increased the percentage of individuals with claims identified using the DME file in 2005, as
bills for orally administered agents appear primarily in the DME file. Chemotherapy claims
for breast cancer were largely identified by physician claims in both 2000 and 2005.
The comparisons of any chemotherapy identified by the POC and Medicare claims for the
post-diagnosis periods for each cancer site/year are reported in Table 2. Individuals
receiving chemotherapy according to each data source is reported. Overall, the measures of
agreement and validity for identifying the receipt of any chemotherapy were high for all
cancer sites and post-diagnosis periods, except for the 2- and 4-month periods. Excluding
those periods, Kappa estimates of concordance ranged from 77% – 87%; Se ranged from
84% – 97%, Sp ranged from 78% – 97%, PPVs ranged from 87% – 96%, and NPVs ranged
from 81% – 96%. The Sp estimates for the receipt of any chemotherapy for women
diagnosed with ovarian cancer in 2002 were low in the later post-diagnosis periods. Due to
the small number of women not receiving chemotherapy in the later post-diagnosis periods,
the Sp estimates are unstable. Although the confidence intervals are wide, these intervals
include Sp ranges that are consistent with estimates across other cancer sites. Across all
cancer sites and year, the Sp and Se estimates for the receipt of any chemotherapy did not
vary by patient characteristics (data not shown).
Table 3 describes the measures of agreement and validity for the Medicare claims
definitions used to identify the receipt of specific chemotherapeutic agents during the 6-
month post-diagnosis period. For all intravenous agents administered to patients diagnosed
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with CRC and NSCLC, the measures of concordance and validity were high: Kappa ranged
from 71% – 95%; Se ranged from 75% – 95%; Sp ranged from 90% – 99%; PPV ranged
from 85% – 99%; and NPV ranged from 81% – 97%. Consistently, these measures (Kappa,
Se, and PPV) were lowest for oxaliplatin. The measures of agreement and validity for
identifying capecitabine, an orally administered agent equivalent to the intravenously
administered 5-fluorouracil (5-FU) for CRC, in Medicare claims was poor with Kappa and
Se of only 55% and 47%, respectively.
For breast cancer, the Se estimates for cyclophosphamide and doxorubicin were lower than
other cancer site-agents at 75% and 73%, respectively; however, the 95% confidence
intervals included values consistent with other sites. For ovarian cancer, the Sp estimates for
carboplatin and paclitaxel were low at 78% and 74%, respectively. The Sp estimates for the
specific ovarian cancer agents were lower than agents used to treat other cancer sites across
all post-diagnosis periods (data not shown). Evidence of variation was seen when comparing
the above measures for the same agents across different cancer sites. The Kappa, Se, and Sp
for the receipt of paclitaxel and carboplatin were higher among patient treated for NSCLC as
compared to those treated for ovarian cancer.
Figure 2 illustrates how the use of multiple post-diagnosis periods changes the Se and Sp
estimates for specific chemotherapeutic agents used to treat individuals diagnosed with stage
II and III CRC in 2005. Generally, the Se for specific treatments reach their maximum close
to the 8-month post-diagnosis period, with the exception of oxaliplatin for which Se
continues to climb up to the 12-month post-diagnosis period. The Se of capecitabine is
approximately 50% lower than the Se for all other CRC agents and remains steady over
time. The Sp of Medicare claims for identifying patients who did not receive specific CRC
chemotherapy agents was > 93% for all post-diagnosis periods.
We conducted a sensitivity analysis to assess the impact that potential misclassification of
the gold standard (i.e., the POC studies) could have on our results, using the specific
example of oxaliplatin treatment for CRC patients in 2005. We identified 10 individuals
diagnosed with CRC in 2005 who had 2 or more claims for oxaliplatin during the 12-months
post-diagnosis, but were not identified by POC as having received oxaliplatin as part of the
initial course of treatment. Because physicians would not likely submit claims to Medicare
for administering oxaliplatin (an expensive treatment) unless it was actually delivered, we
assumed that these patients were misclassified by the POC studies. We varied the percentage
of oxaliplatin-treated patients that were missed by the 2005 CRC POC study from 0% to
60% (or 0 to 6 individuals) and assessed the changes in Se, Sp, and PPV. Over the range of
values, the PPV increased the most from 84% to 94%, while the Se and Sp remained nearly
constant, increasing only from 89% to 90% and 96% to 98%, respectively (data not shown).
Discussion
We found that utilizing 6, 8, 10, or 12 months of Medicare claims following a primary
diagnosis of in situ or early stage breast, stage II or III colorectal, non-small cell lung, or
ovarian cancer can accurately identify whether an individual received any chemotherapy as
part of their initial course of treatment. However, the ability of Medicare claims to identify
the receipt of specific chemotherapeutic agents appeared to vary by the agent, cancer site,
and mode of administration. Medicare claims used to identify intravenously administered
agents for CRC and NSCLC generally had a high Se, Sp, PPV, and NPV; although the Se
tended to increase using longer post-diagnosis periods for more recently approved agents
(i.e., oxaliplatin). The Se and Sp estimates for identifying any chemotherapy treatment
among individuals diagnosed with breast and ovarian cancers were generally lower than
those for CRC and NSCLC. Across cancer sites, Medicare claims performed best when
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identifying specific agents used to treat NSCLC (i.e., carboplatin and paclitaxel) with all
measures of agreement and validity exceeding 90%.
Our findings update a prior study by Warren et al(32) utilizing POC data (1991, 1995, and
1996) to assess the utility of Medicare claims data for identifying the receipt of
chemotherapy among individuals diagnosed with in situ or early stage breast, stage II or III
CRC, and ovarian cancer. We found remarkably similar Kappa and Se estimates for
identifying the receipt of any chemotherapy across cancer sites, with all confidence intervals
encompassing the prior study estimates. However, our Kappa and Se estimates of Medicare
claims for identifying specific chemotherapeutic agents are higher than those reported by
Warren and colleagues. For example, in our study the Se of claims to identify the receipt of
cyclophosphamide for the treatment of ovarian cancer was 75% (Table 3) compared with
only 47% in the earlier study. It is possible that coding and reporting behavior improved
over time, especially with the rising cost of chemotherapy.(42) These updated measures
further confirm the utility of Medicare claims to identify these agents and provide the
relevant information that may be used to correct for misclassification.
Our study extended the Warren study by examining the chemotherapeutic agents that were
not included in the original study, such as doxorubicin for breast cancer, oxaliplatin and
capecitabine for CRC, and paclitaxel for breast and NSCLC. Another study examined the
validity of Medicare claims for identifying specific agents in comparison to two different
clinical trials among breast (1995–1997) and lung (1998–2000) cancer patients. The study
reported the Se and Sp for doxorubicin as 91% (95% CI: 79%, 98%) and 100%, and for
paclitaxel as 86% (79%, 92%) and 100%, consistent with our findings.(29)
This is the first study to examine the validity of Medicare claims to identify oxaliplatin for
individuals diagnosed with stage II and III CRC. The Se of Medicare claims to identify
oxaliplatin increases with the length of the claims window post-diagnosis. A temporary
HCPCS code was available for oxaliplatin (C9205) in 2005, while starting January 1, 2006,
a permanent HCPCS code (J9263) was established. It is possible that physician coding
improved after the permanent code was available, leading to better capture of oxaliplatin in
later post-diagnosis periods.
There have been no prior validation studies examining the reporting of capecitabine in the
Medicare data. We observed consistently low Se estimates for capecitabine in the Medicare
claims for all post-diagnosis periods. One possible explanation for its poor Se is that patients
who cannot afford their copayments received the drug through pharmacy assistance
programs sponsored by the pharmaceutical company. It may also be that patients had
prescription drug insurance that covered oral medications and the patient or the provider did
not submit a claim for capecitabine to Medicare. Capecitabine is covered under Medicare
Part B, as it is an oral alternative to an intravenous medication (5-FU). Chemotherapeutic
agents that are only in oral form would be covered under Medicare’s Part D prescription
drug coverage, which was implemented in 2006. Using Part D data to identify use of oral
chemotherapies is limited as only 52% of Medicare beneficiaries have Part D enrollment.
(43) Our findings, taken together with limited Part D enrollment among Medicare
beneficiaries, suggest that the reporting of oral chemotherapeutic agents in the Medicare
data may be incomplete. However, additional validation of oral chemotherapeutic agents in
the Medicare data is needed. Two possible approaches to further explore the frequency of
capecitabine claims in the outpatient drug setting would be to link: 1) Medicare dually-
eligible individuals to their Medicaid prescription drug claims or 2) poor, elderly individuals
that meet state pharmacy assistance program thresholds to their outpatient drug claims.
These two groups are particularly unique and therefore results from these analyses may not
be generalizable to the larger Medicare population.
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This study has a number of strengths. Through cooperation with the NCI and SEER
registries, we linked verified treatment data obtained through physician confirmation or
unified medical record review to Medicare claims for a large number of individuals aged
≥65 years and diagnosed with one of four different cancers. The detailed POC data
collection allowed us to assess the validity of Medicare claims to identify specific agents
that have not previously been validated. We examined and reported variation in measures of
validity across different post-diagnosis periods, whereas prior studies primarily used one or
two broad post-diagnosis time windows.(28, 31, 32)
Our study is not without limitations. There may be patients in the study who received
treatment from another healthcare payer (e.g., the Veterans Health Administration). These
claims would not be captured in this analysis. Therefore, our results may be viewed as
minimum thresholds which could be improved by combining information from other payers.
Furthermore, approximately 26% of individuals in the POC studies lacked physician
confirmation or unified medical record review and were therefore excluded from analysis.
We also excluded individuals who had any HMO enrollment during the post-diagnosis
periods, as detailed claims data were not reported to Medicare for these individuals. These
exclusions along with our focus on individuals 65+ years limit the overall generalizability of
our findings. This analysis examined the receipt of chemotherapy as part of the initial course
of treatment, but did not distinguish between adjuvant and neoadjuvant treatment; we would
not expect results to differ based on the receipt of therapy before or after surgery, however.
Similarly, we cannot be sure that claims appearing later in the post-diagnosis period still
relate to the initial course of treatment, or whether they are actually linked to treatment of
recurrent or progressive cancer.
In conclusion, we assessed the utility of Medicare claims to identify the receipt of any
chemotherapy and specific agents. Generally, Medicare claims can accurately identify the
receipt of any chemotherapy and most specific agents administered intravenously. Medicare
claims in combination with clinical data from cancer registries may be a valuable resource
for health services research focused on evaluating treatment-related issues. Additionally,
these results may be useful to assess the potential impact of treatment misclassification in
future studies.
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